Erythropoietin and cancer: The unintended consequences of anemia correction

Frontiers in Immunology

Volumn 5, Issue NOV, 2014, Pages

  Debeljak, Nataša ^a   Solár, Peter ^b   Sytkowski, Arthur J ^c  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

^c IQVIA   (United States)

Author keywords

Angiogenesis; Cancer; Cell response; Clinical trials; Erythropoietin; Erythropoietin receptor; Receptor partners

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; EPHRIN RECEPTOR B4; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; STAT3 PROTEIN; STAT5 PROTEIN; TRASTUZUMAB;

AMINO ACID SEQUENCE; ANEMIA; ANGIOGENESIS; CELL GROWTH; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; LYMPHANGIOGENESIS; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 84919426054     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00563     Document Type: Review

References (187)

1. Carnot P, Deflandre C. Sur l'activité hémopoiétique du sérum au cours de la régénération du sang. C R Acad Sci Paris (1906) 143:384-435.
2. Erslev A. Humoral regulation of red cell production. Blood (1953) 8(4):349-57.
3. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem (1977) 252(15):5558-64.
4. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature (1985) 313(6005):806-10. doi: 10.1038/313806a0
5. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A (1985) 82(22):7580-4. doi:10.1073/pnas.82.22.7580
6. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med (1987) 316(2):73-8. doi:10.1056/NEJM198701083160203
7. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice Procrit Study Group. J Clin Oncol (1997) 15(3):1218-34.
8. Debeljak N, Sytkowski AJ. Erythropoietin and erythropoiesis stimulating agents. Drug Test Anal (2012) 4(11):805-12. doi:10.1002/dta.1341
9. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A (1990) 87(15):5978-82. doi:10.1073/pnas.87.15.5978
10. Digicaylioglu M, Bichet S, Marti HH, Wenger RH, Rivas LA, Bauer C, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci U S A (1995) 92(9):3717-20. doi:10.1073/pnas.92.9.3717
11. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol (2004) 83(11):673-86. doi:10.1007/s00277-004-0911-6
12. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA (2005) 293(1):90-5. doi:10.1001/jama.293.1.90
13. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells from clinic to bench - a critical review. Biochim Biophys Acta (2010) 1806(1):82-95. doi:10.1016/j.bbcan.2010.04.002
14. Powell JS, Berkner KL, Lebo RV, Adamson JW. Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci U S A (1986) 83(17):6465-9. doi:10.1073/pnas.83.17.6465
15. Watkins PC, Eddy R, Hoffman N, Stanislovitis P, Beck AK, Galli J, et al. Regional assignment of the erythropoietin gene to human chromosome region 7pter-q22. Cytogenet Cell Genet (1986) 42(4):214-8. doi:10.1159/000132281
16. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol (2007) 435:179-97. doi:10.1016/S0076-6879(07)35010-6
17. Stockmann C, Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol (2006) 33(10):968-79. doi:10.1111/j.1440-1681.2006.04474.x
18. Rahbek-Nielsen H, RoepstorffP, Reischl H, Wozny M, Koll H, Haselbeck A. Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom (1997) 32(9):948-58. doi:10.1002/(SICI)1096-9888(199709)32:9<948::AID-JMS551>3.0.CO;2-C
19. Lai PH, Everett R, Wang FF, Arakawa T, Goldwasser E. Structural characterization of human erythropoietin. J Biol Chem (1986) 261(7):3116-21.
20. Romanowski RR, Sytkowski AJ. The molecular structure of human erythropoietin. Hematol Oncol Clin North Am (1994) 8(5):885-94.
21. Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T, et al. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry (1992) 31(41):9871-6. doi:10.1021/bi00156a003
22. Dube S, Fisher JW, Powell JS. Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Biol Chem (1988) 263(33):17516-21.
23. Sytkowski AJ, Feldman L, Zurbuch DJ. Biological activity and structural stability of N-deglycosylated recombinant human erythropoietin. Biochem Biophys Res Commun (1991) 176(2):698-704. doi:10.1016/S0006-291X(05)80240-2
24. Bachmann S, Le Hir M, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem (1993) 41(3):335-41. doi:10.1177/41.3.8429197
25. Maxwell PH, Ferguson DJ, Nicholls LG, Iredale JP, Pugh CW, Johnson MH, et al. Sites of erythropoietin production. Kidney Int (1997) 51(2):393-401. doi:10.1038/ki.1997.52
26. Juul SE, Yachnis AT, Christensen RD. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev (1998) 52(3):235-49. doi:10.1016/S0378-3782(98)00030-9
27. Sytkowski AJ. Erythropoietin: Blood, Brain and Beyond. Weinheim: Wiley-VCH (2004).
28. Sytkowski AJ. Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE (2007) 2007(395):e38. doi:10.1126/stke.3952007pe38
29. Recny MA, Scoble HA, Kim Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J Biol Chem (1987) 262(35):17156-63.
30. Spaninger K, Borštnar S, Matos E, Možina B, Sytkowski AJ, Komel R, et al. Report on isoelectric focusing trial of erythropoietin profiling in two cancer patients during chemotherapy and darbepoetin treatment. Acta Chim Slov (2011) 58(1):139-43.
31. Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of isoelectric profiles of erythropoietin in urine: differentiation of natural and administered recombinant hormones. Anal Biochem (2002) 311(2):119-26. doi:10.1016/S0003-2697(02)00407-4
32. Lasne F, Thioulouse J, Martin L, de Ceaurriz J. Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis. Electrophoresis (2007) 28(12):1875-81. doi:10.1002/elps.200600363
33. Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J. Dimerization of the extracellular domain of the erythropoietin (EPO) receptor by EPO: one high-affinity and one low-affinity interaction. Biochemistry (1996) 35(5):1681-91. doi:10.1021/bi9524272
34. N Debeljak AJ Sytkowski. EpoR: Basic Sequence: Mouse. UCSD Nature Molecule Pages. (2007). doi:10.1038/mp.a000863.01
35. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A (2004) 101(41):14907-12. doi:10.1073/pnas.0406491101
36. Jackson DB, Stein M, Voss H, Brock S. Tissue protective erythropoietin receptor (nepor) and methods of use. European Patent Application EP 2 492 355 A1 (2012).
37. Penny LA, Forget BG. Genomic organization of the human erythropoietin receptor gene. Genomics (1991) 11(4):974-80. doi:10.1016/0888-7543(91)90022-7
38. Jones SS, D'Andrea AD, Haines LL, Wong GG. Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood (1990) 76(1):31-5.
39. Winkelmann JC, Penny LA, Deaven LL, Forget BG, Jenkins RB. The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood (1990) 76(1):24-30.
40. Arcasoy MO, Jiang X, Haroon ZA. Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun (2003) 307(4):999-1007. doi:10.1016/S0006-291X(03)01303-2
41. Harris KW, Winkelmann JC. Enzyme-linked immunosorbent assay detects a potential soluble form of the erythropoietin receptor in human plasma. Am J Hematol (1996) 52(1):8-13. doi:10.1002/(SICI)1096-8652(199605)52:1<8::AID-AJH2>3.3.CO;2-O
42. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer (2007) 110(3):477-88. doi:10.1002/cncr.22832
43. Bazan JF. Haemopoietic receptors and helical cytokines. Immunol Today (1990) 11(10):350-4. doi:10.1016/0167-5699(90)90139-Z
44. Bailey SC, Feldman L, Romanowski RR, Davis KL, Sytkowski AJ. Antipeptide antibodies as probes of the recombinant and endogenous murine erythropoietin receptors. Exp Hematol (1993) 21(12):1535-43.
45. Hosoi S, Miyaji H, Satoh M, Kurimoto T, Mihara A, Fujiyoshi N, et al. Optimization of cell culture conditions for production of biologically active proteins. Cytotechnology (1991) 5(Suppl 2):17-34. doi:10.1007/BF00573878
46. McCaffery PJ, Fraser JK, Lin FK, Berridge MV. Subunit structure of the erythropoietin receptor. J Biol Chem (1989) 264(18):10507-12.
47. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci (2005) 6(6):484-94. doi:10.1038/nrn1687
48. Brines M, Cerami A. The receptor that tames the innate immune response. Mol Med (2012) 18:486-96. doi:10.2119/molmed.2011.00414
49. Brines M, Patel NS, Villa P, Brines C, Mennini T, De Paola M, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A (2008) 105(31):10925-30. doi:10.1073/pnas.0805594105
50. Ghezzi P, Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ (2004) 11(Suppl 1):S37-44. doi:10.1038/sj.cdd.4401450
51. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol (2005) 6(6):462-75. doi:10.1038/nrm1690
52. Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol (2006) 169(1):279-93. doi:10.2353/ajpath.2006.050889
53. Noren NK, Pasquale EB. Paradoxes of the EphB4 receptor in cancer. Cancer Res (2007) 67(9):3994-7. doi:10.1158/0008-5472.CAN-07-0525
54. Pelekanou V, Kampa M, Kafousi M, Dambaki K, Darivianaki K, Vrekoussis T, et al. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome. Cancer Epidemiol Biomarkers Prev (2007) 16(10):2016-23. doi:10.1158/1055-9965.EPI-06-1023
55. Trošt N, Hevir N, Rižner TL, Debeljak N. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines. Int J Mol Med (2013) 31(3):717-25. doi:10.3892/ijmm.2013.1231
56. Larsson AM, Jirström K, Fredlund E, Nilsson S, Rydén L, Landberg G, et al. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res (2009) 15(17):5552-9. doi:10.1158/1078-0432.CCR-08-3014
57. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell (2010) 18(5):423-35. doi:10.1016/j.ccr.2010.10.025
58. Reinbothe S, Larsson AM, Vaapil M, Wigerup C, Sun J, Jögi A, et al. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation. Biochem Biophys Res Commun (2014) 445(1):163-9. doi:10.1016/j.bbrc.2014.01.165
59. Pelekanou V, Notas G, Sanidas E, Tsapis A, Castanas E, Kampa M. Testosterone membrane-initiated action in breast cancer cells: interaction with the androgen signaling pathway and EPOR. Mol Oncol (2010) 4(2):135-49. doi:10.1016/j.molonc.2010.01.004
60. Notas G, Kampa M, Pelekanou V, Castanas E. Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: a pharmacological approach. Steroids (2012) 77(10):943-50. doi:10.1016/j.steroids.2011.11.005
61. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol (2008) 141(1):14-31. doi:10.1111/j.1365-2141.2008.07014.x
62. Mastromarino V, Musumeci MB, Conti E, Tocci G, Volpe M. Erythropoietin in cardiac disease: effective or harmful? J Cardiovasc Med (Hagerstown) (2013) 14(12):870-8. doi:10.2459/JCM.0b013e328362c6ae
63. Sorg H, Harder Y, Krueger C, Reimers K, Vogt PM. The nonhematopoietic effects of erythropoietin in skin regeneration and repair: from basic research to clinical use. Med Res Rev (2013) 33(3):637-64. doi:10.1002/med.21259
64. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist (2004) 9(Suppl 5):18-30. doi:10.1634/theoncologist.9-90005-18
65. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res (2006) 12(2):332-9. doi:10.1158/1078-0432.CCR-05-1771
66. Udupa KB. Functional significance of erythropoietin receptor on tumor cells. World J Gastroenterol (2006) 12(46):7460-2. doi:10.3748/wjg.v12.i46.7460
67. Jeong JY, Feldman L, Solar P, Szenajch J, Sytkowski AJ. Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells. Int J Cancer (2008) 122(2):274-80. doi:10.1002/ijc.23068
68. Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer (2007) 43(3):510-9. doi:10.1016/j.ejca.2006.10.012
69. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, et al. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer (2010) 1(1):50-61. doi:10.1177/1947601909356352
70. Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest (2014) 124(2):553-63. doi:10.1172/JCI69804
71. Todaro M, Turdo A, Bartucci M, Iovino F, Dattilo R, Biffoni M, et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res (2013) 73(21):6393-400. doi:10.1158/0008-5472.CAN-13-0248
72. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal (2007) 19(3):634-45. doi:10.1016/j.cellsig.2006.08.014
73. Miller CP, Lowe KA, Valliant-Saunders K, Kaiser JF, Mattern D, Urban N, et al. Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial. Stem Cells (2009) 27(9):2353-61. doi:10.1002/stem.156
74. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ. Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate (2006) 66(2):135-45. doi:10.1002/pros.20310
75. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, et al. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene (2005) 24(27):4442-9. doi:10.1038/sj.onc.1208635
76. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int (2000) 58(2):647-57. doi:10.1046/j.1523-1755.2000.00211.x
77. Abhold E, Rahimy E, Wang-Rodriguez J, Blair KJ, Yu MA, Brumund KT, et al. Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro. BMC Res Notes (2011) 4:553. doi:10.1186/1756-0500-4-553
78. Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C, et al. Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer (2011) 129(11):2566-76. doi:10.1002/ijc.25935
79. Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ, Feldman L. An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res (2009) 7(7):1150-7. doi:10.1158/1541-7786.MCR-08-0243
80. Wu P, Zhang N, Wang X, Zhang C, Li T, Ning X, et al. The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells. PLoS One (2012) 7(9):e45122. doi:10.1371/journal.pone.0045122
81. Solár P, Hrcková G, Varinská L, Solárová Z, Kriška J, Uhrínová I, et al. Location and the functionality of erythropoietin receptor(s) in A2780 cells. Oncol Rep (2012) 28(1):141-6. doi:10.3892/or.2012.1795
82. Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ. Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions. J Hematol Oncol (2013) 6:65. doi:10.1186/1756-8722-6-65
83. Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, Acs G. RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol (2009) 174(4):1504-14. doi:10.2353/ajpath.2009.080592
84. Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H, et al. Erythropoietin receptor expression in human melanoma cells. Melanoma Res (2000) 10(5):421-6. doi:10.1097/00008390-200010000-00003
85. Shiozawa Y, McGee S, Pienta MJ, McGregor N, Jung Y, Yumoto K, et al. Erythropoietin supports the survival of prostate cancer, but not growth and bone metastasis. J Cell Biochem (2013) 114(11):2471-8. doi:10.1002/jcb.24592
86. Swift S, Ellison AR, Kassner P, McCaffery I, Rossi J, Sinclair AM, et al. Absence of functional EpoR expression in human tumor cell lines. Blood (2010) 115(21):4254-63. doi:10.1182/blood-2009-10-248674
87. Pérès EA, Valable S, Guillamo JS, Marteau L, Bernaudin JF, Roussel S, et al. Targeting the erythropoietin receptor on glioma cells reduces tumour growth. Exp Cell Res (2011) 317(16):2321-32. doi:10.1016/j.yexcr.2011.06.011
88. Akiyama M, Kawano T, Mikami-Terao Y, Agawa-Ohta M, Yamada O, Ida H, et al. Erythropoietin activates telomerase through transcriptional and posttranscriptional regulation in human erythroleukemic JAS-REN-A cells. Leuk Res (2011) 35(3):416-8. doi:10.1016/j.leukres.2010.11.002
89. Aguilar C, Aguilar C, Lopez-Marure R, Jiménez-Sánchez A, Rocha-Zavaleta L. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2. Mol Med Rep (2014) 9(5):1895-902. doi:10.3892/mmr.2014.2044
90. Hedley BD, Chu JE, Ormond DG, Beausoleil MS, Boasie A, Allan AL, et al. Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res (2011) 17(19):6151-62. doi:10.1158/1078-0432.CCR-10-3298
91. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest (2002) 82(7):911-8. doi:10.1097/01.LAB.0000020415.72863.40
92. Inbar D, Cohen-Armon M, Neumann D. Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation. Br J Cancer (2012) 107(8):1317-26. doi:10.1038/bjc.2012.395
93. Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells. Breast Cancer Res Treat (2012) 136(3):739-48. doi:10.1007/s10549-012-2316-x
94. Ferracin M, Bassi C, Pedriali M, Pagotto S, D'Abundo L, Zagatti B, et al. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression. Mol Cancer (2013) 12(1):130. doi:10.1186/1476-4598-12-130
95. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int (1993) 43(5):1010-4. doi:10.1038/ki.1993.142
96. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int (1995) 47(3):740-5. doi:10.1038/ki.1995.113
97. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A (1994) 91(9):3974-8. doi:10.1073/pnas.91.9.3974
98. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, et al. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem (1996) 239(2):494-500. doi:10.1111/j.1432-1033.1996.0494u.x
99. Haller H, Christel C, Dannenberg L, Thiele P, Lindschau C, Luft FC. Signal transduction of erythropoietin in endothelial cells. Kidney Int (1996) 50(2):481-8. doi:10.1038/ki.1996.339
100. Janmaat ML, Heerkens JL, de Bruin AM, Klous A, de Waard V, de Vries CJ. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood (2010) 115(7):1453-60. doi:10.1182/blood-2009-07-230870
101. Kriška J, Solár P, Varinská L, Solárová Z, Kimáková P, Mojžiš J, et al. Human erythropoietin increases the pro-angiogenic potential of A2780 ovarian adenocarcinoma cells under hypoxic conditions. Oncol Rep (2013) 30(3):1455-62. doi:10.3892/or.2013.2566
102. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R. Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem (1998) 273(39):25381-7. doi:10.1074/jbc.273.39.25381
103. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood (1999) 93(8):2627-36.
104. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol (2003) 163(3):993-1000. doi:10.1016/S0002-9440(10)63459-1
105. Kertesz N, Wu J, Chen TH, Sucov HM, Wu H. The role of erythropoietin in regulating angiogenesis. Dev Biol (2004) 276(1):101-10. doi:10.1016/j.ydbio.2004.08.025
106. Yasuda Y, Fujita Y, Musha T, Tanaka H, Shiokawa S, Nakamatsu K, et al. Expression of erythropoietin in human female reproductive organs. Ital J Anat Embryol (2001) 106(2 Suppl 2):215-22.
107. Yasuda Y, Fujita Y, Masuda S, Musha T, Ueda K, Tanaka H, et al. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis (2002) 23(11):1797-805. doi:10.1093/carcin/23.11.1797
108. Nakamatsu K, Nishimura Y, Suzuki M, Kanamori S, Maenishi O, Yasuda Y. Erythropoietin/erythropoietin-receptor system as an angiogenic factor in chemically induced murine hepatic tumors. Int J Clin Oncol (2004) 9(3):184-8. doi:10.1007/s10147-004-0399-z
109. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H. Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia (2008) 10(9):932-9.
110. Rupertus K, Senger S, Menger MD, Schilling MK, Kollmar O. Darbepoetin-alpha promotes neovascularization and cell proliferation in established colorectal liver metastases. J Surg Res (2012) 176(2):517-23. doi:10.1016/j.jss.2011.09.062
111. Nico B, Annese T, Guidolin D, Finato N, Crivellato E, Ribatti D. Epo is involved in angiogenesis in human glioma. J Neurooncol (2011) 102(1):51-8. doi:10.1007/s11060-010-0294-6
112. Kumar SM, Zhang G, Bastian BC, Arcasoy MO, Karande P, Pushparajan A, et al. Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene (2012) 31(13):1649-60. doi:10.1038/onc.2011.366
113. Yang J, Xiao Z, Li T, Gu X, Fan B. Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int J Oncol (2012) 40(4):1230-7. doi:10.3892/ijo.2011.1261
114. Pascual M, Bohle B, Alonso S, Mayol X, Salvans S, Grande L, et al. Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J Surg Res (2013) 183(1):270-7. doi:10.1016/j.jss.2012.12.041
115. Ribatti D. Erythropoietin and tumor angiogenesis. Stem Cells Dev (2010) 19(1):1-4. doi:10.1089/scd.2009.0402
116. Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A, et al. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology (2007) 50(5):591-6. doi:10.1111/j.1365-2559.2007.02654.x
117. Ribatti D, Nico B, Perra MT, Longo V, Maxia C, Annese T, et al. Erythropoietin is involved in angiogenesis in human primary melanoma. Int J Exp Pathol (2010) 91(6):495-9. doi:10.1111/j.1365-2613.2010.00731.x
118. Ribatti D, Poliani PL, Longo V, Mangieri D, Nico B, Vacca A. Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology (2007) 50(5):636-41. doi:10.1111/j.1365-2559.2007.02654.x
119. Li HG, Li JS, Chen WL, Wang L, Wu DH, Lin ZY. Prognostic significance of erythropoietin and erythropoietin receptor in tongue squamous cell carcinoma. Br J Oral Maxillofac Surg (2009) 47(6):470-5. doi:10.1016/j.bjoms.2009.06.001
120. Wang L, Li HG, Xia ZS, Wen JM, Lv J. Prognostic significance of erythropoietin and erythropoietin receptor in gastric adenocarcinoma. World J Gastroenterol (2011) 17(34):3933-40. doi:10.3748/wjg.v17.i34.3933
121. Lee AS, Kim DH, Lee JE, Jung YJ, Kang KP, Lee S, et al. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res (2011) 71(13):4506-17. doi:10.1158/0008-5472.CAN-10-3787
122. McKinney M, Arcasoy MO. Erythropoietin for oncology supportive care. Exp Cell Res (2011) 317(9):1246-54. doi:10.1016/j.yexcr.2011.03.003
123. Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst (2013) 105(14):1018-26. doi:10.1093/jnci/djt145
124. Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev (2012) 12:CD003407. doi:10.1002/14651858.CD003407.pub5
125. Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, et al. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus >/= 10 g/dL: an exploratory analysis of a phase 3 trial. Med Oncol (2012) 29(3):2291-9. doi:10.1007/s12032-011-0103-x
126. Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, et al. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia. Curr Med Res Opin (2012) 28(1):57-67. doi:10.1185/03007995.2011.639352
127. Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, et al. Randomised, phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer (2011) 105(9):1267-72. doi:10.1038/bjc.2011.395
128. Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer - results at the time of surgery. Ann Oncol (2011) 22(9):1988-98. doi:10.1093/annonc/mdq709
129. Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer - outcome on prognosis. Ann Oncol (2011) 22(9):1999-2006. doi:10.1093/annonc/mdq713
130. Villegas A, Arrizabalaga B, Fernández-Lago C, Castro M, Mayans JR, González-Porras JR, et al. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response. Curr Med Res Opin (2011) 27(5):951-60. doi:10.1185/03007995.2011.561834
131. Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer (2011) 117(16):3641-9. doi:10.1002/cncr.25972
132. Roddy JV, Partridge SM, Rockey ML, Pruemer JM, Guo JJ, Desai SJ, et al. Thromboembolic events in patients with colorectal cancer receiving the combination of bevacizumab-based chemotherapy and erythropoietin stimulating agents. Am J Clin Oncol (2010) 33(1):36-42. doi:10.1097/COC.0b013e31819cccaf
133. Aapro M, Van Erps J, MacDonald K, Soubeyran P, Muenzberg M, Turner M, et al. Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer (2009) 45(1):8-11. doi:10.1016/j.ejca.2008.09.036
134. Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer (2009) 101(12):1961-71. doi:10.1038/sj.bjc.6605255
135. Gascon P, Pirker R, Del Mastro L, Durrwell L. Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. Ann Oncol (2010) 21(10):2029-39. doi:10.1093/annonc/mdq073
136. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet (2009) 373(9674):1532-42. doi:10.1016/S0140-6736(09)60502-X
137. Lambin P, Ramaekers BL, van Mastrigt GA, Van den Ende P, de Jong J, De Ruysscher DK, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer. Cochrane Database Syst Rev (2009) 138(3):CD006158. doi:10.1002/14651858.CD006158.pub2
138. Mäenpää J, Puistola U, Riska H, Sintonen H, Saarni O, Juvonen E, et al. Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: a prospective observational study using the generic 15D instrument. Anticancer Res (2014) 34(5):2325-9.
139. Thomaidis T, Weinmann A, Sprinzl M, Kanzler S, Raedle J, Ebert M, et al. Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. Int J Clin Oncol (2014) 19(2):288-96. doi:10.1007/s10147-013-0544-7
140. Weber B, Largillier R, Ray-Coquard I, Yazbek G, Meunier J, Alexandre J, et al. A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer (2013) 21(7):1947-54. doi:10.1007/s00520-013-1748-0
141. Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci (2013) 104(4):481-5. doi:10.1111/cas.12105
142. Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, et al. Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. Cancer (2013) 119(1):107-14. doi:10.1002/cncr.27686
143. Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA. Cytokine use and survival in the first-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol (2012) 127(3):495-501. doi:10.1016/j.ygyno.2012.09.002
144. Aerts JG, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, et al. Use of darbepoetin alfa in European clinical practice for the management of chemotherapy-induced anaemia in four tumour types: final data from the CHOICE study. Curr Med Res Opin (2012) 28(7):1089-99. doi:10.1185/03007995.2012.698602
145. Van Belle S, Karanikiotis C, Labourey JL, Galid A, Wheeler T, Pujol B. Current practice of darbepoetin alfa in the management of haemoglobin levels in cancer patients undergoing chemotherapy - data from the CHOICE study. Curr Med Res Opin (2011) 27(5):987-94. doi:10.1185/03007995.2011.562493
146. Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, et al. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced anaemia in current European clinical practice. Curr Med Res Opin (2012) 28(7):1079-87. doi:10.1185/03007995.2012.698601
147. Kerkhofs L, Boschetti G, Lugini A, Stanculeanu DL, Palomo AG. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience. Future Oncol (2012) 8(6):751-6. doi:10.2217/fon.12.39
148. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, et al. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer (2012) 118(3):848-55. doi:10.1002/cncr.26341
149. Cantrell LA, Westin SN, Van Le L. The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not affect progression-free or overall survival. Cancer (2011) 117(6):1220-6. doi:10.1002/cncr.25590
150. Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, et al. Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. J Clin Oncol (2011) 29(28):3791-7. doi:10.1200/JCO.2010.30.4899
151. Nagel S, Kellner O, Engel-Riedel W, Guetz S, Schumann C, Gieseler F, et al. Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Clin Lung Cancer (2011) 12(1):62-9. doi:10.3816/CLC.2011.n.009
152. Eisterer W, Hussl C, Erb H, Haslbauer F, Sormann S, Braun S, et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 microg every 3 weeks in anaemic cancer patients receiving chemotherapy. Curr Med Res Opin (2011) 27(2):355-63. doi:10.1185/03007995.2010.542134
153. Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H. The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. BJU Int (2011) 108(10):1582-7. doi:10.1111/j.1464-410X.2011.10173.x
154. Rørth M, Madsen KR, Burmølle SH, Midtgaard J, Andersen C, Nielsen B, et al. Effects of darbepoetin alfa with exercise in cancer patients undergoing chemotherapy: an explorative study. Scand J Med Sci Sports (2011) 21(3):369-77. doi:10.1111/j.1600-0838.2009.01066.x
155. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin theta with a new dosing schedule in anaemic cancer patients receiving nonplatinum-based chemotherapy: a randomised controlled trial. Arch Drug Inf (2011) 4(3):33-41. doi:10.1111/j.1753-5174.2011.00035.x
156. Esquerdo G, Llorca C, Cervera JM, Orts D, Juárez A, Carrato A. Effectiveness of darbepoetin alfa in a cohort of oncology patients with chemotherapy-induced anaemia. Relationship between variation in three fatigue-specific quality of life questionnaire scores and change in haemoglobin level. Clin Transl Oncol (2011) 13(5):341-7. doi:10.1007/s12094-011-0664-3
157. Gómez A, Salgado M, Valladares-Ayerbes M, Jorge M, Carballo A, Candamio S, et al. Efficacy of epoetin-beta 30,000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy. Clin Transl Oncol (2010) 12(12):843-8. doi:10.1007/s12094-010-0607-4
158. Gomez-Alamillo C, Fernández-Fresnedo G, Ortega F, Campistol JM, Gentil MA, Arias M, et al. Erythropoietin resistance as surrogate marker of graft and patient survival in renal transplantation: 3-year prospective multicenter study. Transplant Proc (2010) 42(8):2935-7. doi:10.1016/j.transproceed.2010.07.043
159. Schwartzberg L, Burkes R, Mirtsching B, Rearden T, Silberstein P, Yee L, et al. Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. BMC Cancer (2010) 10:581. doi:10.1186/1471-2407-10-581
160. Ray-Coquard I, Laplaige P, Vey N, Asselain B, Urbieta M. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia. Curr Med Res Opin (2010) 26(11):2653-60. doi:10.1185/03007995.2010.526099
161. Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, et al. Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist (2010) 15(9):935-43. doi:10.1634/theoncologist.2009-0279
162. Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, et al. Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. MEDICC Rev (2010) 12(3):27-31.
163. Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, et al. Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol (2010) 85(9):655-63. doi:10.1002/ajh.21779
164. Maccio A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G, et al. Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. Oncologist (2010) 15(8):894-902. doi:10.1634/theoncologist.2010-0020
165. Ichinose Y, Seto T, Nishiwaki Y, Ohe Y, Yamada Y, Takeda K, et al. Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. Jpn J Clin Oncol (2010) 40(6):521-9. doi:10.1093/jjco/hyq017
166. Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol (2010) 28(13):2239-45. doi:10.1200/JCO.2009.25.1835
167. Muravyov AV, Cheporov SV, Kislov NV, Bulaeva SV, Maimistova AA. Comparative efficiency and hemorheological consequences of hemotransfusion and epoetin therapy in anemic cancer patients. Clin Hemorheol Microcirc (2010) 44(2):115-23. doi:10.3233/CH-2010-1259
168. Stull DE, Vernon MK, Legg JC, Viswanathan HN, Fairclough D, Revicki DA. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue. Contemp Clin Trials (2010) 31(2):172-9. doi:10.1016/j.cct.2009.12.006
169. Tjulandin SA, Bias P, Elsässer R, Gertz B, Kohler E, Buchner A. Epoetin theta in anaemic cancer patients receiving platinum-based chemotherapy: a randomised controlled trial. Arch Drug Inf (2010) 3(3):45-53. doi:10.1111/j.1753-5174.2010.00030.x
170. Hoskin PJ, Robinson M, Slevin N, Morgan D, Harrington K, Gaffney C. Effect of epoetin alfa on survival and cancer treatment-related anemia and fatigue in patients receiving radical radiotherapy with curative intent for head and neck cancer. J Clin Oncol (2009) 27(34):5751-6. doi:10.1200/JCO.2009.22.3693
171. Vansteenkiste J, Dooms C, De Leyn P. The multidisciplinarity of stage III non-small cell lung cancer. Eur J Cancer (2009) 45(Suppl 1):92-105. doi:10.1016/S0959-8049(09)70021-8
172. Grobmyer SR, Hemming AW, Harris N, Behrns K, Logan H, Kim RD, et al. A pilot prospective randomized trial of postoperative epoetin alfa in patients undergoing major operation for upper gastrointestinal malignancy. Am J Clin Oncol (2009) 32(6):570-3. doi:10.1097/COC.0b013e31819790a8
173. Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, et al. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin (2009) 25(9):2109-20. doi:10.1185/03007990903084164
174. Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood (2009) 114(12):2393-400. doi:10.1182/blood-2009-03-211797
175. Repetto LCIPOMO Investigators. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey. Crit Rev Oncol Hematol (2009) 72(2):170-9. doi:10.1016/j.critrevonc.2009.03.004
176. Tzekova V, Mihaylov G, Elezovic I, Koytchev R, Epoetin Zeta Oncology Study Group. Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia. Curr Med Res Opin (2009) 25(7):1689-97. doi:10.1185/03007990903050876
177. Welsch T, Zschäbitz S, Becker V, Giese T, Bergmann F, Hinz U, et al. Prognostic significance of erythropoietin in pancreatic adenocarcinoma. PLoS One (2011) 6(8):e23151. doi:10.1371/journal.pone.0023151
178. Seibold ND, Schild SE, Gebhard MP, Noack F, Schröder U, Rades D. Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R. Strahlenther Onkol (2013) 189(7):559-65. doi:10.1007/s00066-013-0320-7
179. Rades D, Setter C, Dahl O, Schild SE, Noack F. Prognostic impact of erythropoietin expression and erythropoietin receptor expression on locoregional control and survival of patients irradiated for stage II/III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2011) 80(2):499-505. doi:10.1016/j.ijrobp.2010.02.003
180. Lin YT, Chuang HC, Chen CH, Armas GL, Chen HK, Fang FM, et al. Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma. BMC Cancer (2012) 12:194. doi:10.1186/1471-2407-12-194
181. Volgger B, Kurz K, Zöschg K, Theurl I, Ciresa-König A, Marth C, et al. Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer. Anticancer Res (2010) 30(9):3721-6.
182. Giatromanolaki A, Fiska A, Pitsiava D, Kartalis G, Koukourakis MI, Sivridis E. Erythropoietin receptors in endometrial carcinoma as related to HIF1{alpha} and VEGF expression. In vivo (2009) 23(5):699-703.
183. Küster O, Simon P, Mittelbronn M, Tabatabai G, Hermann C, Strik H, et al. Erythropoietin receptor is expressed in meningiomas and lower levels are associated with tumour recurrence. Neuropathol Applied Neurobiol (2009) 35(6):555-65. doi:10.1111/j.1365-2990.2009.01021.x
184. Gombos Z, Danihel L, Repiska V, Acs G, Furth E. Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role of hypoxia in tumorigenesis. Indian J Pathol Microbiol (2011) 54(2):273-8. doi:10.4103/0377-4929.81591
185. Beschorner R, Psaras T, Meyermann R, Bremer J, Schmidt T, Mittelbronn M, et al. Erythropoietin receptor expression in normal and neoplastic choroid plexus. Clin Neuropathol (2011) 30(1):33-40. doi:10.5414/NPP30033
186. Xu C, Zhou T, He M, Sun Y. Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissue. Urol Oncol (2010) 28(3):314-9. doi:10.1016/j.urolonc.2008.09.023
187. Mirmohammadsadegh A, Marini A, Gustrau A, Delia D, Nambiar S, Hassan M, et al. Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol (2010) 130(1):201-10. doi:10.1038/jid.2009.162